Severe visual loss after autologous blood injection for mitomycin-C-associated hypotonous maculopathy.
It has been shown that mitomycin-C increases the success rate of trabeculectomy; however, a rise in the incidence of postoperative complications has also been reported. Consequently, the use of antimetabolite is usually reserved for patients who are at high risk of surgical failure or for patients with advanced glaucoma in whom low intraocular pressure is desired. This report describes a patient who suffered severe visual loss which was a direct result of hypotonous maculopathy after trabeculectomy with mitomycin-C and various other complications from the subsequent interventions.
Lu
D W
DW
William and Anna Goldberg Glaucoma Service and Research Laboratories, Wills Eye Hospital, Jefferson Medical College, Philadelphia, PA 19107, USA.
Azuara-Blanco
A
A
Katz
L J
LJ
D000328:Adult; D001769:Blood; D005902:Glaucoma, Open-Angle / Q000150:complications / Q000601:surgery; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure; D008266:Macula Lutea; D008297:Male; D016685:Mitomycin / Q000009:adverse effects*; D019384:Nucleic Acid Synthesis Inhibitors / Q000009:adverse effects*; D015814:Ocular Hypotension / Q000139:chemically induced / Q000628:therapy*; D012164:Retinal Diseases / Q000139:chemically induced / Q000628:therapy*; D014130:Trabeculectomy / Q000009:adverse effects / Q000379:methods; D014786:Vision Disorders / Q000209:etiology* / Q000503:physiopathology; D014792:Visual Acuity
D019384:Nucleic Acid Synthesis Inhibitors; D016685:Mitomycin